bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
bluebird bio, Inc. (BLUE)
Last bluebird bio, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.bluebirdbio.com/investor-overview
Company Research
Source: Business Wire
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the year ended December 31, 2022, and for each of the first three quarters of 2022 and 2023. Today, the Company filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”), including the restated information, and Form 10-Q for the quarter ended March 31, 2024 (the “Q1 2024 Form 10-Q”) with the Securities and Exchange Commission (“SEC”).As previously disclosed, the restatement related to the identification of leases and the treatment of non-lease components contained in lease agreements. The restatement had no impact on the Company’s cash position or revenue.As a result of the restatement, the Company is delayed in filing its Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”) and is working expeditiously to complete this filing.About bluebird bio, Inc.bluebir
Show less
Read more
Impact Snapshot
Event Time:
BLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLUE alerts
High impacting bluebird bio, Inc. news events
Weekly update
A roundup of the hottest topics
BLUE
News
- Cell & Gene Therapy Manufacturing Services Market Size Worth US$ 70.7 Billion by 2032, Amid Rising Clinical Trials | Research by SNS Insider [Yahoo! Finance]Yahoo! Finance
- bluebird bio, Inc. (NASDAQ: BLUE) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Bluebird: Q1 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- bluebird bio Announces September Investor EventsBusiness Wire
- bluebird bio Announces Receipt of Expected Notices from NasdaqBusiness Wire
BLUE
Earnings
- 11/7/23 - Beat
BLUE
Sec Filings
- 9/16/24 - Form PRE
- 9/13/24 - Form 10-Q
- 9/13/24 - Form 10-K
- BLUE's page on the SEC website